Early neuroprotective effect with lack of long-term cell replacement effect on experimental stroke after intra-arterial transplantation of adipose-derived mesenchymal stromal cells

Choi, Chunggab; Chang, Da Jeong; Shin, Dong Ah; Lee, Nayeon; Jeon, Ik Soo; Sung, Jong Hwan; Lee, Hyunseung; Hong, Kwan Soo; Ko, Jung Jae; Song, Jihwan

doi:10.1016/j.jcyt.2015.04.007

Cited by 43 publications

(39 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2013, Valencia et al 2016). Moreover, intra-arterial delivery of AD-MSCs in an induced model of ischemic stroke attenuated inflammation and led to improved functional recovery, especially during the early phase of ischemia (Oh et al, 2015). In another study of AD-MSC transplantation, this time with the cells delivered intravenously, AD-MSCs were shown to significantly upregulate expression of the potent neuroprotective factors BDNF and TrkB (Li et al, 2016).…”

Section: Identifying the Optimal Cell Type For Stem Cell Transplanmentioning

confidence: 99%

“…Recent studies have shed new light on the cross-talk between endogenous stem cells or grafted stem cells and cells from the immune system (Kokaia et al, 2012; Morganti et al, 2015; Grotenhuis et al, 2016; Krampera et al, 2003). These studies suggest that the regenerative medicine seems heavily influenced by both cell-autonomous and non-cell autonomous mechanism, which are controlled by infiltrating circulating populations of innate (microglia, monocytes, monocyte-derived macrophages) and adaptive immune cells (B and T cells) (Kokaia et al, 2012).…”

Section: “And the Oscar Goes To…”: Bone Marrow-derived Mesenchymalmentioning

confidence: 99%

“…These studies suggest that the regenerative medicine seems heavily influenced by both cell-autonomous and non-cell autonomous mechanism, which are controlled by infiltrating circulating populations of innate (microglia, monocytes, monocyte-derived macrophages) and adaptive immune cells (B and T cells) (Kokaia et al, 2012). Certainly, there is a wide spectrum of concurrent immune responses within the infiltrating circulating population of the immune system including both pro- and anti-inflammatory phenotypes after injury, which will elicit a response in the grafted stem cells population (Morganti et al, 2015). In particular, MHC II phenotype increases collagen deposition and proliferation and gene expression of MMP1 (stimulate cells migration), PLOD2 (critical for stability of intermolecular crosslinks) and PTGS2 (modulate the inflammatory immune response) when MHCII+ macrophages were co-cultured with adipose mesenchymal stem cells (Grotenhuis et al, 2016).…”

Section: “And the Oscar Goes To…”: Bone Marrow-derived Mesenchymalmentioning

confidence: 99%

See 2 more Smart Citations

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stonesifer

Corey

Ghanekar

et al. 2017

Progress in Neurobiology

203

207

View full text Add to dashboard Cite

Ischemic stroke is a leading cause of death worldwide. A key secondary cell death mechanism mediating neurological damage following the initial episode of ischemic stroke is the upregulation of endogenous neuroinflammatory processes to levels that destroy hypoxic tissue local to the area of insult, induce apoptosis, and initiate a feedback loop of inflammatory cascades that can expand the region of damage. Stem cell therapy has emerged as an experimental treatment for stroke, and accumulating evidence supports the therapeutic efficacy of stem cells to abrogate stroke-induced inflammation. In this review, we investigate clinically relevant stem cell types, such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs), very small embryonic-like stem cells (VSELs), neural stem cells (NSCs), extraembryonic stem cells, adipose tissue-derived stem cells, breast milk-derived stem cells, menstrual blood-derived stem cells, dental tissue-derived stem cells, induced pluripotent stem cells (iPSCs), teratocarcinoma-derived Ntera2/D1 neuron-like cells (NT2N), c-mycER(TAM) modified NSCs (CTX0E03), and notch-transfected mesenchymal stromal cells (SB623), comparing their potential efficacy to sequester stroke-induced neuroinflammation and their feasibility as translational clinical cell sources. To this end, we highlight that MSCs, with a proven track record of safety and efficacy as a transplantable cell for hematologic diseases, stand as an attractive cell type that confers superior anti-inflammatory effects in stroke both in vitro and in vivo. That stem cells can mount a robust anti-inflammatory action against stroke complements the regenerative processes of cell replacement and neurotrophic factor secretion conventionally ascribed to cell-based therapy in neurological disorders.

show abstract

Section: Identifying the Optimal Cell Type For Stem Cell Transplanmentioning

confidence: 99%

Section: “And the Oscar Goes To…”: Bone Marrow-derived Mesenchymalmentioning

confidence: 99%

Section: “And the Oscar Goes To…”: Bone Marrow-derived Mesenchymalmentioning

confidence: 99%

See 1 more Smart Citation

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stonesifer

Corey

Ghanekar

et al. 2017

Progress in Neurobiology

203

207

View full text Add to dashboard Cite

show abstract

“…ASC also reduced the size of the infarct, reduced acute brain swelling, improved in myelination, increased vascular supply, reduced scar formation, and decreased chronic atrophy (Fig. A) . These improvements may be secondary to the capacity of ASC to reduce apoptosis, reduce inflammation, reduce glial scar formation, increase angiogenesis, increase neurogenesis, and differentiate into astrocytes and neurons.…”

Section: Resultsmentioning

confidence: 87%

“…In preclinical studies, ASC administered through intravenous and intracarotid injection have shown the potential to reduce disability and improve motor function up to 56 days after ischemic stroke (Fig. A) . ASC also reduced the size of the infarct, reduced acute brain swelling, improved in myelination, increased vascular supply, reduced scar formation, and decreased chronic atrophy (Fig.…”

Section: Resultsmentioning

confidence: 99%

Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies

et al. 2018

View full text Add to dashboard Cite

The objective of this Review is to describe the safety and efficacy of adipose stem/stromal cells (ASC) and stromal vascular fraction (SVF) in treating common diseases and the next steps in research that must occur prior to clinical use. Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients. Sixty-nine studies were performed in preclinical models of disease. ASCs improved symptoms, fistula healing, remission, and recurrence rates in severe cases of inflammatory bowel disease. In osteoarthritis, ASC and SVF improved symptom-related, functional, radiographic, and histological scores. ASC and SVF were also shown to improve clinical outcomes in ischemic stroke, multiple sclerosis, myocardial ischemia, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, chronic liver failure, glioblastoma, acute kidney injury, and chronic skin wounds. These effects were primarily paracrine in nature and mediated through reduction of inflammation and promotion of tissue repair. In the majority of human studies, autologous ASC and SVF from liposuction procedures were used, minimizing the risk to recipients. Very few serious, treatment-related adverse events were reported. The main adverse event was postprocedural pain. SVF and ASC are promising therapies for a variety of human diseases, particularly for patients with severe cases refractory to current medical treatments. Further randomized controlled trials must be performed to elaborate potential safety and efficacy prior to clinical use. Stem Cells 2018;36:1311-1328.

show abstract

Real-Time Dual MRI for Predicting and Subsequent Validation of Intra-Arterial Stem Cell Delivery to the Central Nervous System

Walczak

Janowski

2017

Neuromethods

View full text Add to dashboard Cite

Early neuroprotective effect with lack of long-term cell replacement effect on experimental stroke after intra-arterial transplantation of adipose-derived mesenchymal stromal cells

Cited by 43 publications

References 44 publications

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms

Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies

Real-Time Dual MRI for Predicting and Subsequent Validation of Intra-Arterial Stem Cell Delivery to the Central Nervous System

Contact Info

Product

Resources

About